“There’s no doubt it’s uniquely enabling us to see relationships, pathways, interactions, risks that we couldn’t have seen just by sort of human scouring of data.” ProFound Therapeutics CEO John Lepore tells Bloomberg Intelligence, highlighting the potential to uncover an entirely new set of disease targets beyond the proteins traditionally recognized by science. In this Vanguards of Healthcare podcast episode, Lepore sits down with BI Senior Pharmaceuticals Analyst Sam Fazeli for an in-depth interview about how ProFound is using AI and its ProFoundry platform to explore the “dark proteome” and identify previously undiscovered proteins. The two also discuss how the company combines genetics, proteomics and computational tools to determine which proteins matter in disease and translate those discoveries into potential first-in-class medicines.



